Results 211 to 220 of about 49,422 (253)
Some of the next articles are maybe not open access.
Antibody–Drug Conjugate Payloads
2013Toxin payloads, or drugs, are the crucial components of therapeutic antibody-drug conjugates (ADCs). This review will give an introduction on the requirements that make a toxic compound suitable to be used in an antitumoral ADC and will summarize the structural and mechanistic features of four drug families that yielded promising results in preclinical
Jan, Anderl +3 more
openaire +2 more sources
Antibody-Drug Conjugate Targets
Current Cancer Drug Targets, 2009The requirements for a cell surface molecule to be suitable as an antibody-drug conjugate target are stringent. The notion that antibodies-directed toward targets on the surface of malignant cells could be used for drug delivery is not new. The history of antibody-drug conjugates has been marked by hurdles identified and overcome. Early conjugates used
openaire +2 more sources
Antibody–Drug Conjugates in Tumor Therapy
Pharmaceutical Patent Analyst, 2012Antibody-drug conjugates (ADCs) for tumor therapy contain a cytotoxic drug conjugated to a monoclonal antibody (mAb) across a linker. A homing device, the mAb enables the recognition of tumor cells by binding to tumor-specific antigens. The linker is usually cleaved inside the tumor cell or close to the cell surface according to a well-designed ...
Sammet, Benedikt +2 more
openaire +3 more sources
Payloads of Antibody: Drug Conjugates
2015The payload of antibody–drug conjugates (ADCs) is the warhead of ADCs that kills the tumor cells. Three classes of highly potent toxins including maytansinoids, auristatins, and calicheamicins are currently being employed or pursued in the clinic as the payloads of ADCs.
openaire +1 more source
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Ca-A Cancer Journal for Clinicians, 2022Shanu Modi +2 more
exaly
Current approaches for the purification of antibody–drug conjugates
Journal of Separation Science, 2022Yutaka Matsuda
exaly
Diazaborines Are a Versatile Platform to Develop ROS‐Responsive Antibody Drug Conjugates**
Angewandte Chemie - International Edition, 2021Luis Filipe Veiros +2 more
exaly
Antibody–drug conjugates: Recent advances in payloads
Acta Pharmaceutica Sinica B, 2023Yuxi Wang, , Hanxuan Li
exaly